Vimarsana
Biggest News Aggregation in the World

Sunjay Kaushal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sunjay Kaushal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sunjay Kaushal Today - Breaking & Trending Today

Long-term Survival Data from Longeveron's ELPIS 1 Trial - Vimarsana News

Long-term Survival Data from Longeveron's ELPIS 1 Trial

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to...

Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market - Longeveron (NASDAQ:LGVN), Amgen (NASDAQ:AMGN) - Vimarsana News

Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market - Longeveron (NASDAQ:LGVN), Amgen (NASDAQ:AMGN)

Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat.

Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023 - Longeveron (NASDAQ:LGVN) - Vimarsana News

Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023 - Longeveron (NASDAQ:LGVN)

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal - Vimarsana News

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

19.01.2023 - - Full results published in European Heart Journal Open - - Study met primary safety endpoint - - All patients alive, transplant-free, and maintained expected rate of growth one year after treatment - - Data supports ongoing clinical ... Seite 1

Chicago Congenital Heart Walk raises $167,000 - Vimarsana News

Chicago Congenital Heart Walk raises $167,000

Back in-person, The Children's Heart Foundation led the 2022 Chicago Congenital Heart Walk on June 11 at the Lincoln Park Rowing Lagoon, next to Lincoln Park Zoo. This year, the Chicago walk raised more than $167,000 for heart research, surpassing its initial goal of $110,500.